The Role of Anti-BP180 Antibody Monitoring in Bullous Pemphigoid: An Italian Single-Center Experience
Keywords:
anti-BP180, Bullous Pemphigoid, Autoimmune DisorderAbstract
Introduction: Bullous pemphigoid (BP) is the most common autoimmune blistering disorder, with anti-BP180 antibodies playing a key role in its pathogenesis and diagnosis. However, their utility in disease monitoring remains debated.
Objectives: This study evaluate the role of anti-BP180 antibody monitoring in BP management through a single-center retrospective analysis and literature review.
Methods: We analyzed 149 BP patients diagnosed between 2014 and 2024 at the Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna. Anti-BP180 titers were measured at baseline, six months, and remission. Therapeutic responses and antibody dynamics were assessed and compared with the literature.
Results: Higher baseline anti-BP180 levels correlated with severe disease and prolonged remission times. A ≥60% reduction in titers was associated with successful therapeutic tapering and lower relapse rates. Patients with secondary BP forms exhibited lower baseline titers and faster remission.
Conclusions: Anti-BP180 monitoring serves as a valuable adjunct to clinical assessment, aiding therapeutic decisions, particularly in determining tapering timelines. Nonetheless, integrated approaches combining serological and clinical evaluations remain essential.
References
Aoki V, Miyamoto D. Unfolding the worldwide incidence of bullous pemphigoid: what are we missing? Br J Dermatol 2022;186:386–7. DOI:10.1111/bjd.20838.
Persson MSM, Begum N, Grainge MJ, et al. The global incidence of bullous pemphigoid: a systematic review and meta-analysis. Br J Dermatol 2022;186:414–25. DOI:10.1111/bjd.20743
Bağcı IS, Horváth ON, Ruzicka T, Sárdy M. Bullous pemphigoid. Autoimmun Rev 2017;16:445–55. DOI:10.1016/j.autrev.2017.03.010
Pratasava V, Sahni VN, Suresh A, et al. Bullous Pemphigoid and Other Pemphigoid Dermatoses. Medicina (Kaunas) 2021;57:1061. DOI:10.3390/medicina57101061
Chanprapaph K, Ounsakul V, Pruettivorawongse D, Thadanipon K. Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: A prospective cohort study. Asian Pac J Allergy Immunol 2021;39:272–8. DOI:10.12932/AP-231118-0446
Le Saché-de Peufeilhoux L, Ingen-Housz-Oro S, Hue S, et al. The value of BP230 enzyme-linked immunosorbent assay in the diagnosis and immunological follow-up of bullous pemphigoid. Dermatology 2012;224:154–9. DOI:10.1159/000337545
Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002;30:224–32. DOI:10.1016/s0923-1811(02)00109-3
Lee EH, Kim YH, Kim S, et al. Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid. Ann Dermatol 2012;24:45–55. DOI:10.5021/ad.2012.24.1.45
Muhammed N, Korgaonkar S, Pradhan V, Khopkar US. A Cross-Sectional Study to Correlate Disease Severity in Bullous Pemphigoid Patients with Serum Levels of Autoantibodies Against BP180 and BP230. Indian Dermatol Online J 2021;12:696–700. DOI:10.4103/idoj.IDOJ_813_20
Feng S, Wu Q, Jin P, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Int J Dermatol 2008;47:225–8. DOI:10.1111/j.1365-4632.2008.03473.x
Patsatsi A, Kyriakou A, Pavlitou-Tsiontsi A, et al. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid. Clin Dev Immunol 2012;2012:854795. DOI:10.1155/2012/854795
Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 1997;136:694–8.
Masmoudi W., Vaillant M., Vassileva S., et al. EADV Autoimmune Bullous Skin Disease Task Force (2021). International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid. British J Dermatol, 184(6), 1106–1112. DOI:10.1111/bjd.19611
Daneshpazhooh M, Ghiasi M, Lajevardi V, et al. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid. Arch Dermatol Res 2018;310:255–9. DOI:10.1007/s00403-018-1817-9
Di Lernia V, Casanova DM, Goldust M, Ricci C. Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment. Dermatol Pract Concept. 2020;10(3):e2020050. Published 2020 Jun 29. DOI:10.5826/dpc.1003a50
Chou P-Y, Yu C-L, Wen C-N, et al. Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis. JAMA Dermatol 2024;160:1192–200. DOI:10.1001/jamadermatol.2024.3425
Verheyden MJ, Bilgic A, Murrell DF. A Systematic Review of Drug-Induced Pemphigoid. Acta Derm Venereol 2020;100:adv00224. Published 2020 Aug 17. DOI:10.2340/00015555-3457
de Nicolas-Ruanes B, Ballester-Martinez A, Garcia-Mouronte E, et al. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid. Int J Mol Sci 2023;24:16786. DOI:10.3390/ijms242316786
Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014;28:1133–40. DOI:10.1111/jdv.12366
Kridin K, Bergman R. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients. JAMA Dermatol 2018;154:1152–8. DOI:10.1001/jamadermatol.2018.2352
Izumi T, Ichiki Y, Esaki C, Kitajima Y. Monitoring of ELISA for anti-BP180 antibodies: clinical and therapeutic analysis of steroid-treated patients with bullous pemphigoid. J Dermatol 2004;31:383–91. DOI:10.1111/j.1346-8138.2004.tb00689.x
Giusti D, Le Jan S, Gatouillat G, et al. Biomarkers related to bullous pemphigoid activity and outcome. Exp Dermatol 2017;26:1240–7. DOI:10.1111/exd.13459
van Beek N, Lüttmann N, Huebner F, et al. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. JAMA Dermatol 2017;153:30–8. DOI:10.1001/jamadermatol.2016.3357
Kalowska M, Ciepiela O, Kowalewski C, et al. Enzyme-linked Immunoassay Index for Anti-NC16a IgG and IgE Auto-antibodies Correlates with Severity and Activity of Bullous Pemphigoid. Acta Derm Venereol 2016;96:191–6. DOI:10.2340/00015555-2101
Liu Y, Wang Y, Chen X, et al. Factors associated with the activity and severity of bullous pemphigoid: a review. Ann Med 2020;52:55–62. DOI:10.1080/07853890.2020.1742367
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Giacomo Clarizio, Alice Massi, Stephano Cedirian, Tullio Brunetti, Alessio Natale, Andrea Gabusi, Federica Filippi, Camilla Loi, Lidia Sacchelli, Michelangelo La Placa, Bianca Maria Piraccini, Federico Bardazzi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
